---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-24-000033"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-12-26T23:59:59+00:00"
generated_at: "2026-05-28T23:20:32.280093+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Serina sells UniverXome subsidiary to Juvenescence affiliate for $10 plus assumption of ~$11.2M debt

## Summary
- Sold UniverXome (holding ReCyte and Reverse Bio) to JuvVentures for $10 and assumption of ~$11.2M secured debt.
- Juvenescence is Serina's largest shareholder; Special Committee approved with third-party valuation.
- UniverXome owned 94.8% of ReCyte and 100% of Reverse Bio, legacy AgeX assets from pre-merger.
- Intellectual property transfer not perfected; buyer bears future filing costs.
- Company makes no warranty beyond express representations; assets fully encumbered by pre-existing debt to buyer.

## SEC filing metadata
- accession: 0001708599-24-000033
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/ser-20241223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-24-000033
- JSON: https://secwatch.observer/filing/0001708599-24-000033.json
- Plain text: https://secwatch.observer/filing/0001708599-24-000033.txt

## Key facts
- M&A Transactions
  Serina Therapeutics, Inc. completed a disposition involving JuvVentures (UK) Limited for assumed approximately $11.2 million of secured debt (closed 2024-12-23).
  - Action: disposition
  - Counterparty: JuvVentures (UK) Limited
  - Consideration: assumed approximately $11.2 million of secured debt
  - Closing: 2024-12-23
  source text: with the intent to revert aged or diseased cells to a healthy and functional state. As consideration for the purchase of UniverXome, Juvenescence assumed approximately $11.2 million of secured debt owed by UniverXome to Juvenescence in addition to a nominal cash payment. The debt assumed by Juvenescence was secured by substantially all of the assets of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/0001708599-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.